Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
收藏数据链接：
官方服务：
资源简介：
Progression-free survival ratio
创建时间：
2023-08-04
